Dbv Technologies (DBVTF) 72.0000 $DBVTF
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
